Lupin shares in focus after exclusive deal with Chinese firm for diabetes, obesity management drug

The drug is a fortnightly, or once-in-two weeks, injectable GLP-1. It is indicated for Type 2 diabetes and weight management, Lupin stated in its exchange filing.

Leave a Reply

Your email address will not be published. Required fields are marked *